Horace Mann (HMN) Q3 Earnings and Revenues Surpass Estimates

Horace Mann (HMN) reported robust Q3 results, with adjusted earnings of $1.36 per share significantly surpassing the Zacks Consensus Estimate of $1.05, a 29.52% surprise, and revenues reaching $438.5 million, exceeding expectations by 1.78%. This marks the fourth consecutive quarter the insurer has beaten EPS forecasts. Despite its year-to-date stock performance of 12.8% trailing the S&P 500, the company holds a Zacks Rank #2 (Buy) due to favorable estimate revisions, suggesting potential near-term outperformance.

Analysis

Horace Mann (HMN) reported robust Q3 2025 results, with adjusted earnings of $1.36 per share significantly surpassing the Zacks Consensus Estimate of $1.05, marking a +29.52% surprise. This performance represents the fourth consecutive quarter HMN has exceeded EPS estimates, demonstrating consistent operational strength. Revenues also beat expectations, reaching $438.5 million, a 1.78% beat over consensus and an increase from $412.1 million year-over-year.

Despite these strong results, HMN's shares have underperformed the S&P 500 year-to-date, gaining 12.8% versus the index's 16.5%. However, the stock holds a Zacks Rank #2 (Buy) due to favorable estimate revisions prior to the release, suggesting potential for near-term outperformance. The "Insurance - Multi line" industry, to which HMN belongs, is also favorably positioned in the top 36% of Zacks industries.

The sustainability of HMN's stock movement post-earnings will largely hinge on management's commentary during the upcoming earnings call. Investors should closely monitor any revisions to the current consensus estimates, which project Q4 EPS of $1.22 on $437.05 million in revenues and full-year EPS of $4.31 on $1.7 billion. The strong correlation between estimate revisions and near-term stock performance makes these updates critical.

Key Decisions for Investors

• Monitor management's commentary on the earnings call for forward guidance and any potential shifts in future earnings estimates, which are crucial for sustained price movement.
• Consider the positive Zacks Rank #2 (Buy) and the favorable industry classification as potential indicators for near-term outperformance, despite the stock's year-to-date underperformance against the S&P 500.
• Evaluate HMN's consistent EPS beats over the past four quarters as a sign of strong operational execution, but also note that revenue beats have been less frequent.